A Phase 3 interventional study of Placebo and mRNA-1345 in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 34 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 3rd largest by enrollment, is one of 4 that started in 2023, is one of 4 in phase 3, and was the 6th registered.
656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.
Browse Virus Diseases studies →None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5
First in 2020; this study’s year is marked. 4 started in 2023.
This study's enrollment of 1,900 is above the median of 100 across 464 interventional studies indexed under Virus Diseases.
Median enrollment 579 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
47 studies in Virus Diseases by Moderna, Inc.: 2 open now, 6 under way, 1 of them phase 3. Of 40 finished, 17 (43%) have results posted.
Among the 47 studies in Virus Diseases by Moderna, Inc., this one is the 12th largest by enrollment of the 37 interventional ones that give a count, is one of 14 that started in 2023, is one of 11 in phase 3, and was the 33rd registered.
Moderna, Inc.’s Virus Diseases studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, from their registry updates:
Among Moderna, Inc.’s 47 in Virus Diseases:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when coadministered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults ≥65 years of age. The study will examine the impact of Fluzone HD on the immune response to mRNA-1345 against RSV-A and RSV-B, as well as the impact of mRNA-1345 on the immune response to Fluzone HD against 4 vaccine-matched Influenza A and B strains.
Key Inclusion Criteria:
Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by:
Key Exclusion Criteria:
Note: Other protocol-defined inclusion and/or exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Fluzone HD + mRNA-1345 by intramuscular (IM) injection on Day 1 followed by placebo by IM injection on Day 22.
Biological: Placebo · Biological: mRNA-1345 · Biological: Fluzone HD
Participants will receive Fluzone HD + placebo by IM injection on Day 1 followed by mRNA-1345 by IM injection on Day 22.
Biological: Placebo · Biological: mRNA-1345 · Biological: Fluzone HD
0.9% sodium chloride (normal saline) injection
Suspension for injection
Suspension for injection
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Within 7 days after Day 1 injection
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Within 7 days after Day 22 injection
Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 21 days after Day 1 injection
Number of Participants With Unsolicited AEs Up to 21 Days After Day 22 Injection
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 21 days after Day 22 injection
Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Day 202
Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (nAbs)
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.
Time frame: Day 22 (for Arm 1) and Day 43 (for Arm 2)
GMT of Serum Anti-Hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Austria and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B.
Time frame: Day 22
Percentage of Participants With Seroresponse for RSV-A and RSV-B nAbs, as Measured by HAI Assay
Seroresponse at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.
Time frame: Baseline to Day 22 (for Arm 1) or Day 43 (for Arm 2)
Geometric Mean Fold-Rise (GMFR) of Postinjection RSV-A and RSV-B nAbs Antibodies for Influenza, as Measured by HAI Assay
95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Day 22 (for Arm 1) or Day 43 (for Arm 2)
Percentage of Participants With ≥2-fold Increase in RSV-A and RSV-B nAbs
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.
Time frame: Day 22 (Arm 1) or Day 43 (Arm 2)
Percentage of Participants With Seroconversion, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Austria and Phuket strains. Seroconversion at a participant level was defined as a titer ≥1:40 if baseline is \< 1:10 or at least a 4-fold increase from baseline if baseline was ≥1:10. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B.
Time frame: Day 22
GMFR of Serum Ab Level, as Measured by HAI Assay
95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Day 22
Number of Deaths Related to Study Drug
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
Time frame: Day 1 through Day 202
| Milestone | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| Started | 950 | 950 |
| Received day 1 injection | 946 | 947 |
| Received day 22 injection | 919 | 911 |
| Safety set | 947 | 946 |
| Completed | 914 | 909 |
| Not completed | 36 | 41 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Lost to follow-up | 17 | 19 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Serious adverse reaction (sar)/reactogenicity event | 1 | 1 |
| Withdrew: Withdrawal by subject | 12 | 15 |
| Withdrew: Other than specified | 2 | 1 |
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection | 689 | 547 |
Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 22 Injection | 251 | 557 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| Number of Participants With Unsolicited Adverse Events (AEs) Up to 21 Days After Day 1 Injection | 72 | 72 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| Number of Participants With Unsolicited AEs Up to 21 Days After Day 22 Injection | 60 | 71 |
A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| MAAEs | 194 | 191 |
| AESIs | 0 | 1 |
| SAEs | 23 | 33 |
| AEs Leading to Discontinuation | 3 | 3 |
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.
| IU/mL | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| RSV-A | 11800.26 (11063.69 to 12585.87) | 18874.12 (17670.37 to 20159.87) |
| RSV-B | 4197.74 (3949.53 to 4461.54) | 6579.15 (6178.21 to 7006.11) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Austria and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B.
| titer | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| Influenza A H1N1 Antibody | 108.11 (99.76 to 117.15) | 124.15 (114.49 to 134.62) |
| Influenza A H3N2 Antibody | 198.53 (183.61 to 214.67) | 228.83 (211.50 to 247.58) |
| Influenza B Austria Antibody | 105.32 (98.34 to 112.80) | 118.27 (110.37 to 126.74) |
| Influenza B Phuket Antibody | 33.17 (31.28 to 35.17) | 34.97 (32.97 to 37.10) |
Seroresponse at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.
| percentage of participants | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| RSV-A | 64.7 (61.4 to 67.8) | 78.2 (75.3 to 80.9) |
| RSV-B | 48.7 (45.3 to 52.0) | 61.9 (58.5 to 65.2) |
95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| RSV-A | 6.49 (6.03 to 6.99) | 10.00 (9.25 to 10.82) |
| RSV-B | 4.08 (3.81 to 4.36) | 5.92 (5.48 to 6.39) |
≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B.
| percentage of participants | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| RSV-A | 85.4 (82.9 to 87.6) | 93.2 (91.3 to 94.8) |
| RSV-B | 75.4 (72.5 to 78.2) | 83.5 (80.8 to 85.9) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Austria and Phuket strains. Seroconversion at a participant level was defined as a titer ≥1:40 if baseline is \< 1:10 or at least a 4-fold increase from baseline if baseline was ≥1:10. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B.
| percentage of participants | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| Influenza A H1N1 Antibody | 56.0 (52.7 to 59.3) | 59.0 (55.6 to 62.2) |
| Influenza A H3N2 Antibody | 60.3 (57.0 to 63.5) | 65.8 (62.6 to 68.9) |
| Influenza B Austria Antibody | 55.5 (52.2 to 58.8) | 59.1 (55.8 to 62.4) |
| Influenza B Phuket Antibody | 31.7 (28.6 to 34.8) | 32.8 (29.7 to 36.1) |
95% CI for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| Influenza A H1N1 Antibody | 5.21 (4.76 to 5.71) | 5.78 (5.25 to 6.36) |
| Influenza A H3N2 Antibody | 6.20 (5.64 to 6.82) | 7.16 (6.49 to 7.89) |
| Influenza B Austria Antibody | 4.87 (4.48 to 5.30) | 5.64 (5.17 to 6.16) |
| Influenza B Phuket Antibody | 2.73 (2.56 to 2.90) | 2.88 (2.70 to 3.07) |
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
| Participants | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| Deaths | 2 | 2 |
| Deaths related to study drug | 0 | 0 |
Collected over All-cause mortality and serious adverse events were collected Day 1 up to Day 202. Other (not including serious) unsolicited adverse events were collected up to 21 days after each study injection (that is, Day 1 up to Day 21 for the first injection and Day 22 up to Day 43 for the second injection).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluzone HD + mRNA-1345 Followed by Placebo | 2/950 (0.2%) | 23/947 (2.4%) | 0/947 (0%) |
| Fluzone HD + Placebo Followed by mRNA-1345 | 2/950 (0.2%) | 33/946 (3.5%) | 0/946 (0%) |
| Event | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 |
|---|---|---|
| PneumoniaInfections and infestations | 2/947 | 3/946 |
| Angina unstableCardiac disorders | 0/947 | 2/946 |
| Atrial fibrillationCardiac disorders | 2/947 | 2/946 |
| Coronary artery diseaseCardiac disorders | 0/947 | 2/946 |
| BradycardiaCardiac disorders | 2/947 | 0/946 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/947 | 1/946 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/947 | 0/946 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/947 | 1/946 |
| Bacterial sepsisInfections and infestations | 0/947 | 1/946 |
| COVID-19Infections and infestations | 0/947 | 1/946 |
The Randomized Set included all participants who were randomized in the study, regardless of the participant's treatment status in the study.
| Age, Continuous(years) | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 | Total |
|---|---|---|---|
| Mean | 70.7 ± 4.80 | 70.7 ± 4.80 | 70.7 ± 4.80 |
| Sex: Female, Male(Participants) | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 | Total |
|---|---|---|---|
| Female | 548 | 530 | 1078 |
| Male | 402 | 420 | 822 |
| Ethnicity (NIH/OMB)(Participants) | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 | Total |
|---|---|---|---|
| Hispanic or Latino | 209 | 222 | 431 |
| Not Hispanic or Latino | 728 | 722 | 1450 |
| Unknown or Not Reported | 13 | 6 | 19 |
| Race (NIH/OMB)(Participants) | Fluzone HD + mRNA-1345 Followed by Placebo | Fluzone HD + Placebo Followed by mRNA-1345 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 7 | 2 | 9 |
| Asian | 13 | 12 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 187 | 191 | 378 |
| White | 735 | 738 | 1473 |
| More than one race | 7 | 3 | 10 |
| Unknown or Not Reported | 1 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2023 to primary completion in Jun 2024, 8 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
Of 40 industry-sponsored phase 3 interventional studies under Virus Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 24. This study's 8 months is below that.
Counting every sponsor, half of 57 studies reached it within 14 months; a quarter within 8 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine